For diabetes management, the target HbA1c is typically below 7% for most adults, though individualized targets may be appropriate based on age, comorbidities, and hypoglycemia risk
The nausea associated with Retatrutide typically peaks during weeks 6-8 and diminishes significantly thereafter
An HbA1c check should be scheduled at around 3 months after stopping, as earlier measurements may not fully reflect the change in glycaemic control
Phase 2 clinical trial data published in the New England Journal of Medicine (Jastreboff et al., 2023) demonstrated mean body weight reductions of up to approximately 24% over 48 weeks in adults with obesity a notable finding, though long-term durability data and head-to-head comparisons with other treatments are not yet available
Read more: Lemme Burn: Do these metabolism gummies really help you lose weight
Phase III trials showed visceral fat reduction of about 12-20% over 26 weeks of daily 2 mg dosing
